Citi Research Increases Price Target, EPS Estimates for Agilent | GenomeWeb

NEW YORK (GenomeWeb News) – Citi Research analyst Amit Bhalla has increased his price target on Agilent Technologies' stock from $43 to $50 and has increased earnings-per-share estimates for the firm.

In a research note published last night Bhalla said that Citi has upped its FY 2013 EPS estimate for Agilent to $3.04 from $3.00 and FY 2014 EPS estimate to $3.40 from $3.29. He also said he believes Agilent will produce organic revenue growth of 4 percent to 5 percent for 2014 and 2015, rather than the 3 percent originally modeled by the bank.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.